Veradermics ratios data for the quarter ended Jun 2026. These financial ratios cover 2 quarters of results from Mar 2026 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Mar2026 | Jun2026 |
|---|---|---|
| Efficiency | ||
| Assets AverageAssets Avg. | 274.99M | 611.55M |
| Valuation | ||
| Price to EarningsP/E | -47.77 | -218.55 |
| Price to BookP/B | 3.67 | 6.31 |
| Enterprise Value | 1,042.97M | 4,316.56M |
| EV to EBIT | -34.93 | -146.06 |
| EV to EBITDA | -34.93 | -146.06 |
| Market Capitalization | 1,433.77M | 5,136.45M |
| Price to FCFP/FCF | -67.08 | -352.29 |
| EV to FCF | -48.80 | -296.06 |
| EV to CFO | -49.20 | -297.69 |
| Return Ratios | ||
| Return on Capital Employed [ROCE]ROCE | -14.74% | |
| Return on Assets [ROA]ROA | -12.88% |